YU28199A - Novi oblik jedinjenja - Google Patents

Novi oblik jedinjenja

Info

Publication number
YU28199A
YU28199A YU28199A YU28199A YU28199A YU 28199 A YU28199 A YU 28199A YU 28199 A YU28199 A YU 28199A YU 28199 A YU28199 A YU 28199A YU 28199 A YU28199 A YU 28199A
Authority
YU
Yugoslavia
Prior art keywords
novel compound
compound form
omeprazole
provides
medicine
Prior art date
Application number
YU28199A
Other languages
English (en)
Inventor
Martin Bohlin
Karol Horvath
Sverkee Von Unge
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU28199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of YU28199A publication Critical patent/YU28199A/sh
Publication of RS49685B publication Critical patent/RS49685B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Pronalazak prikazuje S-omeprazol u neutralnom obliku, i karakteriše ga time što se nalazi u čvrstom stanju, poželjno u delimično kristalnom ili u potpuno kristalnom obliku, kao što su oblik A i oblik B. Dalje, pronalazak daje prikaz postupka za dobijanje S-omerprazola, kao i upotrebu S-omeprazola u medicini.[The invention provides S-omeprazole in a neutral form characterised in that it is in a solid state, preferably in a partly crystalline or substantially crystalline state, such as form A or form B. Furthermore, the invention provides processes for the preparation of S- omeprazole and its use in medicine.
YUP-281/99A 1996-12-20 1997-12-16 Novi oblik jedinjenja RS49685B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Publications (2)

Publication Number Publication Date
YU28199A true YU28199A (sh) 2002-03-18
RS49685B RS49685B (sr) 2007-11-15

Family

ID=20405146

Country Status (37)

Country Link
US (1) US6162816A (sh)
EP (1) EP0946547B1 (sh)
JP (1) JP4402174B2 (sh)
KR (1) KR20000069595A (sh)
CN (1) CN1109684C (sh)
AR (1) AR010361A1 (sh)
AT (1) ATE236898T1 (sh)
AU (1) AU730129B2 (sh)
BR (1) BR9714059A (sh)
CA (1) CA2274076C (sh)
CZ (1) CZ294784B6 (sh)
DE (1) DE69720774T2 (sh)
DK (1) DK0946547T3 (sh)
EE (1) EE03923B1 (sh)
EG (1) EG24414A (sh)
ES (1) ES2194231T3 (sh)
HK (1) HK1022909A1 (sh)
HU (1) HU227589B1 (sh)
ID (1) ID21850A (sh)
IL (1) IL130450A0 (sh)
IS (1) IS1981B (sh)
MY (1) MY117032A (sh)
NO (1) NO317191B1 (sh)
NZ (1) NZ336024A (sh)
PL (1) PL190377B1 (sh)
PT (1) PT946547E (sh)
RS (1) RS49685B (sh)
RU (1) RU2184734C2 (sh)
SA (1) SA97180739B1 (sh)
SE (1) SE510666C2 (sh)
SI (1) SI0946547T1 (sh)
SK (1) SK285151B6 (sh)
TR (1) TR199901410T2 (sh)
TW (1) TW538039B (sh)
UA (1) UA55436C2 (sh)
WO (1) WO1998028294A1 (sh)
ZA (1) ZA9711046B (sh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) * 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CN100562318C (zh) * 2000-05-15 2009-11-25 武田药品工业株式会社 晶体的制备方法
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
ATE353887T1 (de) * 2002-06-27 2007-03-15 Reddys Lab Ltd Dr Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
US7612098B2 (en) * 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
US20060247277A1 (en) * 2003-02-28 2006-11-02 Yatendra Kumar Polymorphs of s-omeprazole
ATE508124T1 (de) 2003-03-24 2011-05-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von amorphem rabeprazole-natrium-salz
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1885711A1 (en) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US20090082572A1 (en) * 2005-11-14 2009-03-26 Hetero Drugs Limited Process for amorphous esomeprazole
NZ568471A (en) * 2005-12-05 2010-09-30 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
SI1973896T1 (sl) 2005-12-28 2009-08-31 Union Quimico Farma Postopek priprave (S) - enantiomere omeprazola
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
US8222422B2 (en) 2008-03-10 2012-07-17 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
SG181535A1 (en) 2009-12-08 2012-07-30 Codexis Inc Synthesis of prazole compounds
US9267159B2 (en) 2010-12-08 2016-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
CN1138534C (zh) * 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂

Also Published As

Publication number Publication date
CA2274076C (en) 2008-09-30
HUP0001547A3 (en) 2002-06-28
CN1109684C (zh) 2003-05-28
TR199901410T2 (xx) 1999-08-23
NO993068L (no) 1999-06-21
IS5070A (is) 1999-06-07
NZ336024A (en) 2001-02-23
JP2001507025A (ja) 2001-05-29
JP4402174B2 (ja) 2010-01-20
DE69720774D1 (de) 2003-05-15
EP0946547A1 (en) 1999-10-06
EP0946547B1 (en) 2003-04-09
BR9714059A (pt) 2000-05-09
PT946547E (pt) 2003-07-31
AR010361A1 (es) 2000-06-07
NO993068D0 (no) 1999-06-21
EE9900259A (et) 2000-02-15
ATE236898T1 (de) 2003-04-15
SE510666C2 (sv) 1999-06-14
IL130450A0 (en) 2000-06-01
RU2184734C2 (ru) 2002-07-10
CZ220299A3 (cs) 2000-02-16
PL190377B1 (pl) 2005-12-30
SA97180739B1 (ar) 2006-05-20
RS49685B (sr) 2007-11-15
CZ294784B6 (cs) 2005-03-16
CN1241183A (zh) 2000-01-12
SK285151B6 (sk) 2006-07-07
HK1022909A1 (en) 2000-08-25
SI0946547T1 (en) 2003-10-31
HU0001547D0 (sh) 2002-05-29
SE9604793L (sv) 1998-06-21
UA55436C2 (uk) 2003-04-15
US6162816A (en) 2000-12-19
MY117032A (en) 2004-04-30
ZA9711046B (en) 1998-06-22
ID21850A (id) 1999-08-05
EE03923B1 (et) 2002-12-16
PL334297A1 (en) 2000-02-14
AU5502698A (en) 1998-07-17
SK76599A3 (en) 1999-12-10
HUP0001547A2 (hu) 2002-05-29
KR20000069595A (ko) 2000-11-25
DK0946547T3 (da) 2003-06-30
HU227589B1 (en) 2011-09-28
CA2274076A1 (en) 1998-07-02
TW538039B (en) 2003-06-21
WO1998028294A1 (en) 1998-07-02
EG24414A (en) 2009-05-25
AU730129B2 (en) 2001-02-22
IS1981B (is) 2005-01-14
ES2194231T3 (es) 2003-11-16
SE9604793D0 (sv) 1996-12-20
DE69720774T2 (de) 2004-02-05
NO317191B1 (no) 2004-09-13

Similar Documents

Publication Publication Date Title
MY117032A (en) A novel compound form.
ZA977524B (en) Process for the preparation of bone cements comprising active compound.
AU6076198A (en) Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers
YU15299A (sh) Farmaceutski sastavi
HUP0003265A3 (en) Nutritional composition for the treatment of pressure ulcers
EP0811595A4 (en) HYDROCHALCONE DERIVATIVES, COSMETIC COMPOSITIONS CONTAINING THEM AND PROCESSES FOR PREPARING SUCH DERIVATIVES OR COMPOSITIONS
AU5242000A (en) Nematicidal trifluorobutenes
HK1045693A1 (en) Bicyclic compounds composition and method for stabilizing the same.
EP0604182A3 (en) HIV protease inhibiting compounds.
AU4851397A (en) Compositions for the preparation of leather
ZA9710322B (en) Process for the preparation of benzyl-ethers.
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
BG102818A (en) D-manitol and method for its preparation
CA2340728A1 (en) Methods of treating hypertension and compositions for use therein
AU5563298A (en) Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
EP0622384A3 (de) Verfahren zur Herstellung von Polymerpolyesterolen.
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
AU7986098A (en) 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
ZA968550B (en) Novel processes for the preparation of anti-malarial compounds.
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
EP0635482A3 (de) Verfahren zur Herstellung von mehrfach fluorierten Nitrobenzolen.
ZA971036B (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections.
ZA975637B (en) Method for the treatment of emesis.